BeiGene regains full global rights to tislelizumab after terminating Novartis license agreement

BeOne Medicines Ltd.

On September 17, 2023, BeiGene Switzerland and Novartis mutually terminated the Collaboration and License Agreement for tislelizumab, effective immediately.
BeiGene regains full global rights to develop, manufacture, and commercialize tislelizumab with no royalty payments due to Novartis.
Novartis may continue ongoing clinical trials and conduct future combination trials with tislelizumab subject to BeiGene's approval.
Novartis will provide transition services including manufacturing, regulatory, safety, and clinical support for tislelizumab.
The termination covers licensed territories: US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, Japan.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BeOne Medicines Ltd. terminated Mutual Termination and Release Agreement with Novartis Pharma AG (effective 2023-09-17).

Action: termination
Agreement: collaboration
Counterparty: Novartis Pharma AG
Effective: 2023-09-17

Exact text from the filing

On September 17, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Agreement”) to mutually terminate the License Agreement, effective immediately.

View on SEC.gov

Browse all material agreements →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.